



PDPs Continue to Keep the Promise

Product development partnerships (PDPs) remain the chief developers of innovative, new medical technologies for people suffering with diseases and health threats that are underserved by traditional markets. Beyond their productivity at introducing medical innovations for underserved populations and health crises, PDPs work highly cost-effectively, develop global research capacity, are essential to achieving long-term health targets like the United Nations Sustainable Development Goals, and have made key contributions to the global response to COVID-19.

Since the release of the *Keeping the Promise* Report in 2021, PDPs have continued to develop and introduce new medical technologies at an impressive rate and low cost, while navigating increased resource and operational challenges resulting from the COVID-19 pandemic. PDPs continue to play an integral role in pandemic response and preparedness, helping to tackle well-established and yet-to-emerge health threats around the world, saving lives and reducing burdens on global health systems.



PDP Impact by the Numbers

79

New medical technologies developed

Since 2010, the twelve PDPs represented in *Keeping the Promise* have delivered 79 new health technologies. Innovations introduced since the release of the report in 2021 include a new HIV/AIDS prevention product, a combination antiretroviral treatment for young children with HIV/AIDS, new treatments for hepatitis C, child-friendly medicines to address relapsing malaria, and new diagnostic technologies for COVID-19 and tuberculosis.

100+

New products in late-stage development

Collectively, this group of twelve PDPs manages a portfolio of nearly 300 new health technologies. More than 100 products in development are in late-stage research (Phase 2 or beyond). Continued investment in PDPs is needed to bring yet another generation of life-saving medical innovations across the finish line so they can benefit those who need them.

700+

Sites across nearly 100 countries experience enhanced research capacity

PDPs conduct their work where the diseases they are fighting are prevalent, performing research around the world, often in low-resource settings. Through their work, this group of twelve PDPs has helped build research capacity and research literacy in 98 countries since 2010. Furthermore, the products developed by PDPs often lead to reduced burdens on local health programs and care providers, increasing their capacity to respond to health threats.

2.4+
BILLION

Treatments, tests, and other health tools delivered to people around the world

The products developed by PDPs have reached more than 2.4 billion people, mostly in low- and middle-income countries. This is a conservative estimate, as PDPs typically work with commercialization partners upon market approval for new products and often have incomplete data on the full scope of their reach.